REDLAMP 9: Prognostic Factors for Clinical Outcomes in Patients with Plasmablastic Lymphoma

Plasmablastic lymphoma is an aggressive diffuse large B-cell lymphoma commonly associated with HIV infection, and an unfavorable diagnosis. Though it’s also often found in immunocompetent patients. The Journal of Hematology & Oncology recently published a clinicopathologic analysis of patients with plasmablastic lymphoma, and measured their outcomes. In this video, Dr. John Allan explains the results of this study, and offers takeaways for patients with this aggressive lymphoma.

Previous #REDLAMP entries can be viewed on our Youtube channel.

We encourage you to follow the Lymphoma Program on Twitter, Youtube, and Facebook where we will highlight new videos are about research publications as they are released. We also welcome your feedback, suggestions and questions about this project. If you have other questions about our lymphoma program or clinical trials or would like to see one of our lymphoma specialists, please contact us at 212-746-2919.

Author: lymphomaprogram

Located on the Upper East Side of New York City, the Lymphoma Program at Weill Cornell Medical College/NewYork Presbyterian Hospital is internationally recognized for our efforts to enable patients with non-Hodgkin lymphoma, Hodgkin disease and related disorders to have the best possible clinical outcome, including cure when possible.

Post a Comment

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: